Home › Down Syndrome › Wisconsin › Madison
Down Syndrome clinical trials in Madison, WI
4 studies for Down Syndrome are looking for participants at sites in and around Madison (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
RecruitingObservational study
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Collaboration for Down Syndrome Progress (CDP)
RecruitingObservational study
- University of Wisconsin-Madison, Madison
Trial-Ready Cohort-Down Syndrome (TRC-DS)
RecruitingObservational study
- University of Wisconsin - Madison, Waisman Center, Co-Enrolling through ABC-DS Only, Madison
About Down Syndrome
About 1 in 700 babies are born with the birth defect known as Down Syndrome. Learn about the different Down Syndrome types and related health issues.
More about Down Syndrome on MedlinePlus
Down Syndrome trials in other cities
- Aurora, CO7 studies
- Houston, TX6 studies
- Phoenix, AZ6 studies
- Durham, NC6 studies
- Cincinnati, OH5 studies
- Nashville, TN5 studies
- Kansas City, KS5 studies
- Orlando, FL5 studies
- Ann Arbor, MI5 studies
- Cleveland, OH5 studies
- Philadelphia, PA5 studies
- Atlanta, GA4 studies
Other studies in Madison
- Prostate Cancer29 studies
- Colorectal Cancer22 studies
- Breast Cancer22 studies
- Metastatic Cancer21 studies
- Non-Small Cell Lung Cancer16 studies
- Acute Myeloid Leukemia16 studies
- Melanoma15 studies
- Cancer (all types)14 studies
- Ovarian Cancer13 studies
- Stomach Cancer11 studies
- Lung Cancer10 studies
- Pancreatic Cancer10 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.